In the journal, Pituitary, a new article was recently published reporting MRI follow-up and surveillance recommendations following pituitary surgery. However, despite the endocrinologists and neurosurgeons MRI preferences, 28% of the physicians responding to a survey reported that they were not aware of the concerns related to gadolinium retention by the body.

Maria Fleseriu, MD, director of the Pituitary Center at Oregon Health and Science University in Portland, Oregon responded to the survey results by saying “Pituitary MRI remains a mainstay for follow-up in pituitary disease patients, but further data is needed on the clinical consequences of the contrast agent retention and on the relative toxicities of the different type of agents used. Using non-contrast MRI might be a possibility with the advent of higher-resolution non-contrast MRIs for the follow-up of some pituitary tumors.”

To read the full article: https://www.healio.com/endocrinology/neuroendocrinology/news/in-the-journals/%7Bc43906a9-b47e-429b-9713-e2f10dc0de51%7D/better-knowledge-of-gadolinium-retention-risks-needed-for-pituitary-tumor-mris

We urge our readers to educate their doctors about the results of the latest studies showing the retention of gadolinium by various tissues in the body.

Please join the growing list of advocates and sign our petition so we can help promote the development of safer alternatives and effective treatments to remove gadolinium from patients affected by it.